

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO

(1) PROPOSED ISSUANCE OF UNLISTED WARRANTS UNDER SPECIFIC MANDATE; AND

(2) CONNECTED TRANSACTION — PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHIEF COMMERCIAL OFFICER

Reference is made to (i) the announcement of Ascentage Pharma Group International (the “**Company**”) dated July 14, 2021 (the “**Warrant Issuance Announcement**”) in relation to, among other things, the proposed issuance of the Warrants to Innovent under the Specific Mandate; and (ii) the announcements of the Company dated May 21, 2021, May 26, 2021, July 14, 2021 and July 23, 2021 in relation to, among other things, the proposed grant of RSUs to each of Dr. Sidransky, Mr. Ye, Dr. Yin, Mr. Ren and Mr. Zhu (the “**RSU Scheme Announcements**”, and together with the Warrant Issuance Announcement, the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, a circular containing, among other things, (i) further details of the issue of the Warrants and the Warrant Shares upon exercise thereof; (ii) further details of the proposed grant of RSUs to each of Dr. Sidransky, Mr. Ye, Dr. Yin, Mr. Ren and Mr. Zhu; (iii) the letters from the Independent Board Committees; (iv) the letter from the Independent Financial Adviser; (v) a notice convening the EGM; and (vi) other information as required under the Listing Rules is expected to be despatched to the Shareholders on or before July 31, 2021.

As additional time is required to prepare and finalise certain information to be included in the circular, it is expected that the despatch date of the circular will be postponed to a date falling on or before August 31, 2021.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, July 30, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.